Dr. Finn on AMG900 in Breast Cancer

Richard S. Finn, MD
Published: Monday, Dec 02, 2013

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.

AMG900, a small molecule inhibitor of aurora kinases, may have a potential benefit for patients with p53 mutations, Finn says. These mutations are common throughout all the molecular subtypes of breast cancer but triple-negative breast cancer (TNBC) shows a higher frequency of these mutations.

Finn says these findings suggest that p53 mutations may act as a biomarker for selecting patients who will benefit from AMG900. AMG900 is now in a phase I study that includes patients with TNBC. A biomarker component will be included in the study to help researchers get a better understanding of how the drug is working, Finn says.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.

AMG900, a small molecule inhibitor of aurora kinases, may have a potential benefit for patients with p53 mutations, Finn says. These mutations are common throughout all the molecular subtypes of breast cancer but triple-negative breast cancer (TNBC) shows a higher frequency of these mutations.

Finn says these findings suggest that p53 mutations may act as a biomarker for selecting patients who will benefit from AMG900. AMG900 is now in a phase I study that includes patients with TNBC. A biomarker component will be included in the study to help researchers get a better understanding of how the drug is working, Finn says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x